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OBJECTIVE—In a genome-wide association scan, the rs738409
CG single nucleotide polymorphism (SNP) in the patatin-like
phospholipase 3 gene (PNPLA3) was strongly associated with
increased liver fat but not with insulin resistance estimated from
fasting values. We investigated whether the SNP determines liver
fat independently of visceral adiposity and whether it may even
play a role in protecting from insulin resistance.
RESEARCH DESIGN AND METHODS—Liver fat was mea-
sured by
1H magnetic resonance spectroscopy and total and
visceral fat by magnetic resonance tomography in 330 subjects.
Insulin sensitivity was estimated during an oral glucose tolerance
test and the euglycemic-hyperinsulinemic clamp (n  222).
PNPLA3 and tumor necrosis factor- mRNA and triglyceride
content were measured in liver biopsies from 16 subjects.
RESULTS—Liver fat correlated strongly with insulin sensitivity
(P  0.0001) independently of age, sex, total fat, and visceral fat.
G allele carriers of the SNP rs738409 had higher liver fat (P 
0.0001) and an odds ratio of 2.38 (95% CI 1.37–4.20) for having
fatty liver compared to C allele homozygotes. Interestingly,
insulin sensitivity (oral glucose tolerance test: P  0.99; clamp:
P  0.32), serum C-reactive protein levels, lipids, or liver
enzymes (all P  0.14) were not different among the genotypes.
Additional adjustment for liver fat actually revealed increased
insulin sensitivity in more obese carriers of the G allele (P 
0.01). In liver biopsies triglyceride content correlated positively
with expression of the proinﬂammatory gene tumor necrosis
factor- in C allele homozygotes (n  6, P  0.027) but not in G
allele carriers (n  10, P  0.149).
CONCLUSIONS—PNPLA3 may be an important key to under-
stand the mechanisms discriminating fatty liver with and without
metabolic consequences. Diabetes 58:2616–2623, 2009
N
onalcoholic fatty liver disease (NAFLD) is the
most common chronic hepatic disease in Western
countries affecting more than 25% of adults and
38% of obese children. It constitutes a major risk
factor for progression to liver failure, cirrhosis, and hepato-
cellular carcinoma (1,2). In addition, NAFLD is strongly
associated with insulin resistance and atherosclerosis, inde-
pendently of other risk factors such as total and visceral
adiposity (3–14). Moreover, NAFLD is becoming increasingly
recognized as a condition strongly involved in the pathogen-
esis of the epidemically spreading metabolic diseases type 2
diabetes and cardiovascular disease (10,11).
Metabolic consequences of fatty liver are hyperglyce-
mia, dyslipidemia, and subclinical inﬂammation (12–14).
As an underlying hepatic molecular mechanism, fatty acids
in the liver promote a hepatic inﬂammatory response,
which is referred to as lipotoxicity or nonalcoholic steato-
hepatitis (NASH). This condition induces hepatic insulin
resistance and is often, but not always, accompanied by
elevation of serum liver enzymes and increased serum
levels of C-reactive protein (CRP) (6,14). Furthermore, fat
accumulation in the liver induces the production of the
glycoprotein fetuin-A that impairs insulin signaling in
insulin-sensitive tissues (15,16), promotes cytokine ex-
pression in human monocytes and in animals in vivo (17),
and is a determinant of incident diabetes and cardiovas-
cular disease (18–20).
Most recently, a genome-wide association (GWA) scan
identiﬁed an unrecognized gene that is putatively strongly
involved in the pathogenesis of hepatic steatosis (21,22).
One nonsynonymous variant clearly stood out from the
tested single nucleotide polymorphisms (SNPs), encoding
an isoleucine to methionine substitution at amino acid 148
in patatin-like phospholipase 3 (PNPLA3), also known as
adiponutrin. This SNP (rs738409) was strongly associated
with increased hepatic fat content, measured by
1HMR
(magnetic resonance) spectroscopy, in more than 2,000
individuals, supporting that PNPLA3 is an important can-
didate gene for fatty liver (21). However, this genetic
variant was only moderately associated with elevated
serum liver enzymes and did not correlate with serum
lipids, relationships that are commonly found in humans
with fatty liver (3–6,12). More importantly, and unexpect-
edly, the SNP was not associated with insulin resistance
estimated from fasting glucose and insulin values (21).
It has not been solved whether the relationship of the
SNP with liver fat is mediated by total and/or visceral
adiposity, strong determinants of hepatic steatosis. First,
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fat, measured by
1HMR spectroscopy, independently of
total and visceral fat, precisely measured by magnetic
resonance tomography. Second, because of the unex-
pected ﬁnding of no relationship of the SNP with insulin
resistance, we tested whether the SNP determines insulin
sensitivity, precisely measured during a 2-h 75-g oral
glucose tolerance test (OGTT) and during the euglycemic-
hyperinsulinemic clamp, and subclinical inﬂammation.
Third, because hepatic insulin resistance is often associ-
ated with hepatic inﬂammation, we investigated the
associations of mRNA expression of PNPLA3 and the
proinﬂammatory gene tumor necrosis factor (TNF)-
with triglyceride content and the effect of the SNP on
these relationships in human liver tissue.
RESEARCH DESIGN AND METHODS
Metabolic data from 330 whites from the southern part of Germany were
included in the analyses. They participated in an ongoing study on the
pathophysiology of type 2 diabetes (23). Individuals were included into the
study when they fulﬁlled at least one of the following criteria: a family history
of type 2 diabetes, a BMI 27 kg/m
2, previous diagnosis of impaired glucose
tolerance, or gestational diabetes. All subjects had measurements of body fat
distribution determined by magnetic resonance imaging. They were consid-
ered healthy according to a physical examination and routine laboratory tests.
As assessed by means of a standard questionnaire, the participants had no
history of liver disease such as hepatitis and did not consume more than two
alcoholic drinks per day.
Data from 16 individuals (6 women, 10 men, age 66  9 years, BMI 24  4
kg/m
2) undergoing liver surgery because of hepatic carcinoma or liver
metastasis were also included in the present study. They tested negative for
viral hepatitis and had no liver cirrhosis. Informed written consent was
obtained from all participants, and the local medical ethics committee had
approved the protocol.
Body fat distribution and liver fat. Waist circumference was measured at
the midpoint between the lateral iliac crest and lowest rib. Furthermore, we
measured total and visceral fat with an axial T1-weighed fast spin echo
technique with a 1.5 T whole-body imager (Magnetom Sonata, Siemens
Healthcare) (24). Volunteers were in prone position and images were re-
corded from ﬁngers to toes with a slice thickness of 10 mm and a gap between
slices of 10 mm. Segmentation of images was performed by semiautomatic
thresholding based on a Matlab routine (Mathworks). Visceral fat was
quantiﬁed in 16 to 21 slices (depending on the size of the volunteer) between
femoral heads and diaphragm, not differentiating between intra- and retroper-
itoneal fat, by manual delineation of the visceral compartment. Fat volume
from images was calculated by multiplying the in-plane pixel dimensions with
the slice thickness and the number of pixels classiﬁed as fat. Volumes between
contiguous slices are calculated by simply doubling the volume of the adjacent
slice. Liver fat was measured as previously described (23) by localized
1HMR
spectroscopy, applying a single-voxel STEAM technique with a short echo
time (TE  10 ms) and a long repetition time (TR  4 s) avoiding T2-related
signal losses. Volunteers were in supine position, and a single element of the
spine array coil was used for acquisition of spectroscopic data. Spectra were
recorded in posterior part of segment seven from a volume of interest of 3 
3  2c m
3 in an acquisition time of 2:08 min (32 acquisitions). Volunteers were
asked to be in respiration during data acquisition to minimize movement
artifacts and resulting line broadening. Postprocessing of spectra was per-
formed by manual integration of water signal (H2O at 4.7 ppm) and sum of
methylene (CH2 at 1.3 ppm) and methyl signals (CH3 at 0.95 ppm). Liver fat is
given by Si((CH2)n  CH3)/Si(H2O)  100, where Si is the corresponding signal
integral in arbitrary units.
OGTT. All individuals underwent a 75-g OGTT. We obtained venous plasma
samples at 0, 30, 60, 90, and 120 min for determination of plasma glucose and
insulin. Glucose tolerance was determined according to the 1997 World Health
Organization diagnostic criteria (25).
Euglycemic-hyperinsulinemic clamp. Insulin sensitivity was determined
with a primed insulin infusion at a rate of 40 mU/m
2 p e rm i nf o r2ha s
previously described (23).
Analytical procedures. Blood glucose was determined using a bedside
glucose analyzer (glucose-oxidase method; YSI, Yellow Springs Instruments,
Yellow Springs, CO). Plasma insulin was determined by microparticle enzyme
immunoassay (ADVIA Siemens Healthcare Diagnostics, Eschborn, Germany).
Plasma fetuin-A was determined by an immunoturbidimetric method as
previously described (18,20).
Calculations. The insulin sensitivity index (in micromole per kilogram per
minute per picomole per liter) for systemic glucose uptake was calculated as
the mean infusion rate of glucose (in micromole per kilogram per minute)
necessary to maintain euglycemia during the last 40 min of the euglycemic-
hyperinsulinemic clamp divided by the steady-state plasma insulin concentra-
tion. The latter was the mean insulin concentration at minute 100, 110, and 120
of the clamp (mean for all control subjects: 532  15 pmol/l). Insulin
sensitivity from the OGTT was estimated as proposed by Matsuda and
DeFronzo (26).
Liver samples. Liver samples were taken from normal, nondiseased tissue
during surgery, immediately frozen in liquid nitrogen, and stored at 80°C.
Tissue samples were homogenized in PBS containing 1% Triton X-100 using a
TissueLyser (Qiagen, Hilden, Germany) and triglyceride content was quanti-
ﬁed using the ADVIA 1650 clinical chemistry analyzer (Siemens Healthcare
Diagnostics, Eschborn, Germany).
RNA isolation, RT-PCR, and real-time quantitative PCR analysis. Fro-
zen tissue was homogenized in a TissueLyser (Qiagen), and RNA was
extracted with the RNeasy Tissue Kit (Qiagen) according to the manufactur-
er’s instructions. Reverse transcription of total RNA quantitative PCR of
TNF- and 	-actin was performed on the Light Cycler system (Roche,
Mannheim, Germany) using SYBR green. PNPLA3 mRNA expression was
quantiﬁed using the QuantiTect SYBR Green PCR Kit and Quantitect Primer
Assay QT00055419 (Qiagen) on a Roche LightCycler 480 (Mannheim,
Germany).
Genotyping. For genotyping, DNA was isolated from whole blood using a
commercial DNA isolation kit (NucleoSpin, Macherey & Nagel, Du ¨ren, Ger-
many). The SNP rs738409 in PNPLA3 was genotyped using TaqMan assays
(Applied Biosystems, Foster City, CA). We also genotyped the SNP rs6006460,
although it has a very low allelic frequency in European Americans and was
found to be associated with liver fat only in blacks (21). The TaqMan
genotyping reaction was ampliﬁed on a GeneAmp PCR system 7000 (50°C for
2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1
min), and ﬂuorescence was detected on an ABI Prism sequence detector
(Applied Biosystems). The TaqMan assay was validated by direct sequencing
of the SNPs in 50 control subjects, and both methods gave identical results.
None of the control subjects was polymorphic for the SNP rs6006460. The
genotyping success rate for the SNP rs738409 was 99.9%, and rescreening of
3.3% of the control subjects with the TaqMan assay gave 100% identical results.
Statistical analyses. Data are given as means  SE. Data that were not
normally distributed (e.g., liver fat, insulin sensitivity, body fat distribution;
Shapiro-Wilk W test) were logarithmically transformed. To adjust the effects
of covariates and identify independent relationships, we ﬁrst performed
forward stepwise regression analyses to identify the variables to be included
into a multiple regression model. Next, we performed multivariate linear
regression analyses with these variables as independent parameters. To test
the effect of the genotype on the metabolically relevant parameters, the
parameter to be considered was set as the dependent variable. The genotype
was included in both analyses as an independent nominal variable. For each
dependent variable, two models were applied. In the additive model, the
effects of all possible genotypes on the dependent variable were compared; in
the dominant model homozygotes for the major C allele were compared with
heterozygotes and homozygotes for the minor G allele. The relationship of the
SNPs with insulin sensitivity was also investigated in more lean and more
obese control subjects. Men and women were separately divided by the
median total body fat content into two groups. The lean men and lean women,
as well as the obese men and women, were combined thereafter. Logistic
regression with adjustment for covariates was applied to determine the odds
ratio of the genotypes for being diagnosed with fatty liver. The statistical
software package JMP 4.0 (SAS Institute, Cary, NC) was used.
RESULTS
Subject characteristics and relationships between
parameters of interest. The 330 subjects (130 men and
200 women) had a mean age of 45 (range 18–69) years.
Anthropometrics and metabolic characteristics of the sub-
jects covered a wide range that was particularly large for
total body fat (470 kg), visceral fat (0.2–10.1 kg), liver fat
(0.2–30.0%), and insulin sensitivity (OGTT: 1.6–33.4 arbi-
trary units; clamp: 0.008–0.347 
mol  kg
1  min
1 
pM
1). A total of 105 control subjects had fatty liver (liver
fat 5.56%) (27).
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4.8  0.4%, P  0.0001) and correlated positively with age
(r  0.18, P  0.001), total body fat (r  0.30, P  0.0001),
visceral fat (r  0.59, P  0.0001), and inversely with
insulin sensitivity (OGTT: r  0.53, P  0.0001; clamp:
r  0.56, P  0.0001).
In forward stepwise linear regression analyses including
age, sex, liver fat, total fat, and visceral fat, liver fat was
the strongest determinant of insulin sensitivity estimated
from the OGTT (F ratio: 56) followed by age (F ratio: 9),
total fat (F ratio: 9), and visceral fat (F ratio: 5). Similar
results were found for insulin sensitivity measured by the
clamp (F ratios; liver fat: 39; visceral fat: 12; total fat: 10;
and age: 9).
Relationships between the SNP rs738409 and subject
characteristics. In our population, the frequency of the
minor G allele of the SNP rs738409 in PNPLA3 was 0.26,
similar to ﬁndings in European Americans (0.23) (21), and
the SNP was in Hardy-Weinberg equilibrium (
2 test; P 
0.05). The SNP rs738409 was strongly associated with liver
fat content depicting an allele-dose effect. Carriers of the G
allele had signiﬁcantly higher liver fat compared to C allele
homozygotes, independently of age, sex, and adiposity
(Table 1) and even of visceral adiposity (P  0.0001, Fig.
1A). Furthermore, G allele carriers had higher odds ratios
(CG: 2.15 [95% CI 1.19–3.91]; GG: 3.71 [95% CI 1.37–10.53])
for being diagnosed with fatty liver compared to C allele
homozygotes (Table 1, Fig. 2). However, the predictive
effect of the SNP for diagnosing control subjects with fatty
liver was only moderate (dominant model: positive predic-
tive value of the SNP: 0.51; negative predictive value of the
SNP: 0.61).
Interestingly, the SNP was not associated with insulin
sensitivity estimated from the OGTT (Table 1, Fig. 1B)o r
measured by the clamp (Table 1, P  0.32 after adjustment
for age, sex, total fat, and visceral fat). Power analyses
revealed that at the -level of 0.05 and at a power of 80%
the minimum detectable effect sizes among all three
genotypes (genotypes CC, CG, and GG) were 8.5% for
insulin sensitivity estimated from the OGTT and 9% for
insulin sensitivity measured by the clamp. In a dominant
model (genotype CC vs. CG  GG) the effect sizes were 8%
for insulin sensitivity estimated from the OGTT and 8.3%
for insulin sensitivity measured by the clamp. Further-
more, the SNP was not associated with total fat and
visceral fat, liver enzymes, high-sensitivity (hs)-CRP, or
fetuin-A levels (Table 1). For the liver enzymes, at the
-level of 0.05 and at a power of 80% the minimum
detectable effect sizes among all three genotypes were
7.5% for alanine aminotransferase (ALT) and 5.5% for
aspartate aminotransferase (AST). In a dominant model,
the effect sizes were 7% for ALT and 5% for AST. For
hs-CRP levels, the effect sizes were much larger (all three
genotypes: 21% and dominant model: 19%).
To address in more detail the relationships of the SNP
rs738409 in PNPLA3 with liver fat and insulin sensitivity,
we ﬁrst divided subjects in those with and without fatty
liver. As expected upon deﬁnition liver fat was much
higher in control subjects with fatty liver (Fig. 1C). The
ﬁrst noteworthy ﬁnding was that the SNP was no longer
associated with liver fat content, adjusted for age, sex,
total fat, and visceral fat, once subjects already displayed
fatty liver, possibly because of a ceiling effect. The second
interesting ﬁnding was that in control subjects with fatty
liver, for a very similar liver fat content, carriers of the G
allele appeared to be not just equally but actually more
insulin sensitive than CC homozygotes, and insulin
sensitivity in GG homozygotes was statistically not
different compared to control subjects without fatty
liver (Fig. 1D).
Upon this ﬁnding, based on the data in the literature
showing that PNPLA3 is becoming increasingly expressed
under energy excess (28–31) and because there is an
interaction of the SNP rs738409 with obesity on insulin
TABLE 1
Associations of the SNP rs738409 in PNPLA3 with demographic and metabolic characteristics
Characteristics CC (Ile/Ile) CG (Ile/Met)
GG
(Met/Met)
P (additive
model)
P (dominant
model)
n 188 111 31
Sex (female/male) 115/73 65/46 20/11 0.81* 0.81*
Age (years) 45  14 6  14 5  2 0.76 0.56
Body weight (kg) 87.6  1.3 85.1  1.6 83.7  2.8 0.22 0.08
BMI (kg/m
2) 29.9  0.4 29.1  0.4 28.7  0.8 0.27 0.11
Waist circumference (cm) 97.2  0.96 96.3  1.2 93.1  2.4 0.21 0.15
Total body fat (kg) 26.8  0.8 25.4  1.0 24.9  1.7 0.45 0.21
Visceral fat (kg) 3.03  0.13 2.90  0.17 2.66  0.29 0.34 0.14
Liver fat (%) 5.40  0.48 5.95  0.56 7.18  1.21 0.001 0.005
Fatty liver (liver fat 5.56%) 27% (n  51) 37% (n  41) 42% (n  13) 0.027 0.011
Fasting glucose (mmol/l) 5.29  0.04 5.26  0.05 5.12  0.09 0.21 0.18
2-h glucose (mmol/l) 7.07  0.14 7.09  0.19 7.01  0.31 0.98 0.83
Fasting insulin (pmol/l) 65  46 0  35 5  6 0.81 0.97
2-h insulin (pmol/l) 513  30 467  33 527  73 0.74 0.67
Insulin sensitivity OGTT (arbitrary unit) 12.60  0.51 12.91  0.66 12.88  1.17 0.96 0.78
ISI clamp (
mol  kg
1  min
1  pM
1)† 0.065  0.003 0.065  0.005 0.061  0.006 0.47 0.34
ALT (U/l) 29.3  1.7 27.8  1.2 29.1  2.2 0.44 0.27
AST (U/l) 25.0  0.9 25.0  0.8 23.4  0.9 0.89 0.78
hs-CRP 0.25  0.03 0.25  0.03 0.13  0.02 0.18 0.91
Fetuin-A (
g/ml) 272  4 266  5 266  9 0.71 0.41
Values represent means  SE. For statistical analyses, nonnormally distributed parameters were log transformed. The genotype effect was
tested using an additive and a dominant model. Body weight, BMI, waist circumference, and total body fat were adjusted for age and sex.
The other parameters were additionally adjusted for total body fat. *
2 test. ISI, insulin sensitivity index, †available in 222 control subjects
(C/C n  124; C/G n  72; T/T n  26).
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more lean and more obese by the median total adipose
tissue mass. While in the lean group insulin sensitivity
estimated by the OGTT and adjusted for age, sex, total fat,
visceral fat, and liver fat was not associated with the
genotype (Fig. 3A), it signiﬁcantly increased with increas-
ing copy numbers of the G allele in the obese group (Fig.
3B), indicating a protective effect of the G allele against
insulin resistance.
Because steatosis-induced inﬂammation is accompanied
by insulin resistance, we further investigated in human
liver biopsies the relationships of expression of the proin-
ﬂammatory gene TNF- and of PNPLA3 with the triglyc-
eride content according to the genotype. Both PNPLA3
and TNF- expression correlated positively with triglycer-
ide content (Fig. 4A and B). The SNP was not associated
with TNF- expression (P  0.64). However, liver triglyc-
eride content correlated positively with the expression of
the proinﬂammatory cytokine TNF- in homozygote car-
riers of the C allele (n  6) but not in carriers of the G
allele (n  10, Fig. 4C and D) of the SNP rs738409 in
PNPLA3.
DISCUSSION
Recently, the ﬁrst GWA approach searching for genetic
variants associated with liver fat identiﬁed the rs738409
SNP in PNPLA3, encoding patatin-like phospholipase 3,
also known as adiponutrin, as the variant that was by far
most strongly associated with liver fat content in three
populations (21). In the present study, using precise mea-
surements of liver fat and body fat distribution we con-
ﬁrmed the strong relationship of the SNP with liver fat.
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we provide novel data that this relationship was indepen-
dent of total and visceral adiposity, which are important
determinants of hepatic steatosis (3–6,33). Thus, hepatic
PNPLA3 activity most probably directly affects fat accu-
mulation in the liver, a hypothesis that is supported by our
ﬁnding of a strong positive correlation of hepatic PNPLA3
mRNA expression with liver triglyceride content in liver
tissue samples.
Of note, in the study by Romeo et al. this variant was not
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the three populations or in more than 14,000 control
subjects of the Atherosclerosis Risk in Communities Study
(21). Considering the strong relationship of liver fat with
insulin resistance (3–6,34), this ﬁnding was unexpected.
Therefore, we further investigated whether the SNP
rs738409 in PNPLA3 was associated with insulin sensitiv-
ity estimated from the OGTT and measured by the eugly-
cemic-hyperinsulinemic clamp. The advantage of these
techniques for estimating insulin sensitivity compared to
the use of fasting values, as done in the study of Romeo et
al., is that they provide a more dynamic and precise
measurement of this phenotype. We found no relation-
ships of the SNP with insulin sensitivity in our population.
Furthermore, the SNP was not associated with liver en-
zymes or hs-CRP levels, markers of hepatic and systemic
inﬂammation, which are commonly elevated in insulin
resistance (6,14). Because fetuin-A may be involved in
fatty liver–induced insulin resistance and strongly deter-
mines the incidence of diabetes and cardiovascular dis-
ease (16–20), we further investigated the relationship of
the SNP with circulating fetuin-A. Although liver fat cor-
related with circulating fetuin-A (P  0.01), the SNP was
not associated with fetuin-A levels.
In the study by Romeo et al. (21), the SNP rs738409 was
not associated with ALT or AST levels in more than 1,800
blacks or more than 1,000 European Americans. Only in
597 Hispanics, a signiﬁcant relationship with ALT and AST
levels was found. In a recent GWA approach aiming at
identifying genes inﬂuencing liver enzymes, another SNP
in PNPLA3 (rs2281135), but not the SNP rs738409, was
associated with ALT levels (35). Our ﬁnding of no signiﬁ-
cant association of the SNP with liver enzymes is in
agreement with the ﬁndings of Romeo et al. in blacks and
European Americans. Nevertheless, we cannot exclude
that we may have missed small differences because of the
relatively small sample size. In the study by Romeo et al.,
the relationship of the SNP rs738409 with hs-CRP levels
was not investigated. We did not ﬁnd a signiﬁcant relation-
ship of the SNP rs738409 with hs-CRP levels. For this
analysis we had a low power; therefore, we cannot ex-
clude a relationship of the SNP with this parameter.
Because there was a clear-cut higher liver fat content,
but no increase in insulin resistance in carriers of the
minor G allele compared to C allele homozygotes, we
hypothesized that speciﬁcally PNPLA3-mediated accumu-
lation of liver fat appears to be metabolically benign. If this
was the case, then for a similar amount of liver fat G allele
carriers must be more insulin sensitive than C allele
homozygotes. Indeed, in more obese control subjects,
insulin sensitivity, adjusted for age, sex, total fat, visceral
fat, and liver fat, was higher in carriers of the minor G
allele. Furthermore, in homozygous G allele carriers with
fatty liver, insulin sensitivity was no more signiﬁcantly
different from control subjects without fatty liver, despite
the large difference in liver fat. These data support the
hypothesis that PNPLA3 is involved in the generation of a
metabolically benign fatty liver. Because these ﬁndings are
derived from a more obese smaller subsample of the study
population, the effects of PNPLA3 may be important
particularly in obesity.
Two other genes are also involved in the manifestation
of this interesting condition. One of them is the acyl:CoA:
diacylglycerol acyltransferase 2 (DGAT2) gene that en-
codes the protein DGAT2 that catalyzes the ﬁnal step of
triacylglycerol biosynthesis (36). Liver-speciﬁc Dgat2-
overexpressing mice developed hepatic steatosis with a
ﬁvefold increase in liver triglyceride content compared to
control subjects, but not whole-body or hepatic insulin
resistance (37). Conversely, antisense oligonucleotide
treatment targeting the Dgat2 reduced liver triglycerides
in mice fed a high-fat diet, without improving insulin
sensitivity or glucose tolerance (38). In agreement with
these data we found that a SNP in DGAT2 was associated
with liver fat but not with insulin resistance in humans
(39). Another candidate is the elongation of long-chain
fatty acids (ELOVL) gene (Elovl6). ELOVL catalyzes the
conversion of palmitate to stearate as well as palmitoleate
to vaccinate, thus regulating the hepatic fatty acid compo-
sition (40). Mice deﬁcient for Elovl6 developed obesity and
hepatic steatosis, but not insulin resistance, hyperinsulin-
emia, or hyperglycemia under a high-fat diet (41).
What are the mechanisms leading to this dissociation
between fatty liver and insulin resistance? The paradox of
this ﬁnding may be because of lipotoxicity (42). According
to this concept, triglycerides are probably the least toxic
form in which the lipid excess can be stored in ectopic
tissues, at least in the short-term. The incorporation of
fatty acids into triglycerides, as well as their oxidative
degradation, thus represents protection from lipotoxicity.
However, when these compensatory mechanisms are over-
whelmed, fatty acids induce damage to cells resulting in
impaired metabolism (43,44). Several pathways are thought
to be operative in this process. Among them, activation of
nuclear factor-B and c-Jun NH2-terminal kinase, which are
involved in insulin resistance (14,45,46), are critical. Besides
these proinﬂammatory pathways fatty acid and diacylglyc-
erol (DAG) directly activate protein kinase C-ε , thus inhibit-
ing hepatic insulin signaling (41,47,48).
What is the putative role of PNPLA3/adiponutrin in
these pathways? The function of this protein has not been
completely elucidated. Data in the literature strongly sup-
port that it probably has no lipase activity (49,50) but
rather lipogenic functions in adipose tissue under feed-
ing conditions, particularly under carbohydrate intake
(30,31). It was further hypothesized that if this protein
has similar functions in the liver, then increased hepatic
expression or activity may result in increased triglycer-
ide synthesis (31,49). PNPLA3/adiponutrin was found to
have transacetylase functions and uses DAG as an acyl
acceptor (31,32,49). Therefore, increased activity of the
protein may also result in depletion in the hepatic DAG
and fatty acid content, both of which are involved in
lipotoxicity (47,48). Thus, this protective mechanism may
result in a metabolically benign phenotype under in-
creased lipid load by partitioning excess hepatic fatty
acids to triglycerides that may protect against lipotoxicity.
In support of this hypothesis, we found that in carriers of
the minor rs738409 G allele, the mRNA expression of the
proinﬂammatory gene TNF- in the liver was less strongly
associated with triglyceride content compared to C allele
homozygotes.
What may be the clinical implication of these ﬁndings?
Because fatty liver is becoming a worldwide epidemic, it is
necessary not only to screen for its presence but also for
control subjects at the highest risk for fatty liver–induced
complications. If further studies conﬁrm the role of
PNPLA3/adiponutrin in the generation of steatosis without
complications, then screening for genetic variation in
PNPLA3 may help to stratify this risk.
In conclusion, the SNP rs738409 in PNPLA3 is strongly,
and independently of total and visceral adiposity, associ-
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estimates of liver injury. Mechanisms involved may be
protection from hepatic fatty acid signaling. Therefore,
PNPLA3/adiponutrin may be an important key to under-
stand the mechanisms discriminating fatty liver with
and without metabolic consequences and may serve as a
useful tool for estimating the risk of fatty liver–induced
complications.
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